New Generation of Medical Research
New Generation of Medical Research
Hialeah, Florida, United States7 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Crystal Arthropathies, Nutritional and Metabolic Diseases, arthritic joint disease, arthropathy, gout, hereditary disease, inborn disorder of purine or pyrimidine metabolism, inborn errors of metabolism, metabolic disease, musculoskeletal system disorder, rheumatic disorder | Recruiting | Phase 2 | 2026-09-28 | NCT07535034 | |
| A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout | Uncontrolled Gout | Recruiting | Phase 3 | 2026-09-03 | NCT07388498 | |
| AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF | cardiovascular disorder, heart disorder, heart failure | Recruiting | Phase 2 | 2026-08-27 | NCT06793371 | |
| Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study | Ventricular Outflow Obstruction, aortic valve disorder, aortic valve stenosis, cardiovascular disorder, heart disorder, heart valve disorder | Recruiting | Phase 2 / Phase 3 | 2026-07-06 | NCT07001800 | |
| A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) | Heart; Heart Failure With Preserved Ejection Fraction (HFPEF) | Recruiting | Phase 1 | 2026-04-09 | NCT07219511 | |
| Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, vascular disorder | Active, not recruiting | Phase 3 | 2024-06-04 | NCT05202509 | |
| Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy | Diabetes Complications, Diabetic Cardiomyopathies, Nutritional and Metabolic Diseases, cardiomyopathy, cardiovascular disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, heart disorder, metabolic disease, type 2 diabetes mellitus | Active, not recruiting | Phase 3 | 2022-12-08 | NCT04083339 |